Swetha joined the OMX team in 2021 and combines deep scientific expertise and operational experience to identify and invest in best-in-class companies. She works directly with portfolio companies on IP strategy, pipeline prioritization, and R&D planning.
Prior to OMX, Swetha was an Associate at Flagship Pioneering after completing the Fellows Program in 2018. In this role, she co-founded and operated three new companies in AI/deep learning, agriculture, and cell therapy. Before joining Flagship, she was a postdoctoral fellow at Boston Children’s Hospital / Harvard Medical School developing novel genetic cures for hearing and balance disorders. She received her PhD from the University of Sydney, where she researched new mechanisms and non-opioid therapies for chronic pain conditions.
Education: PhD in Medicine (Neuropharmacology) from the University of Sydney and Bachelor of Biomedical Science from the University of Newcastle
